| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 9 securities · passive | ||||||
|
Veru Inc.
13G/A
VERU · 92536C103
|
1.6% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 1.6% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 1.6% | |||||
| Phillip Gross | 1.6% | |||||
|
Sable Offshore Corp.
13G/A
SOC · 78574H104
|
3.6% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 3.6% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 3.6% | |||||
| Phillip Gross | 3.6% | |||||
|
Syros Pharmaceuticals, Inc.
13G/A
SYRS · 87184Q206
|
2.0% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 2.0% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 2.0% | |||||
| Phillip Gross | 2.0% | |||||
|
Nkarta, Inc.
13G/A
NKTX · 65487U108
|
0% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 0% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 0% | |||||
| Phillip Gross | 0% | |||||
|
Compass Therapeutics, Inc.
13G/A
CMPX · 20454B104
|
4.4% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 4.4% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 4.4% | |||||
| Phillip Gross | 4.4% | |||||
|
TScan Therapeutics, Inc.
13G/A
TCRX · 89854M101
|
7.1% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 7.1% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 7.1% | |||||
| Phillip Gross | 7.1% | |||||
|
Mereo BioPharma Group plc
13G/A
MREO · 589492107
|
5.6% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 5.6% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 5.6% | |||||
| Phillip Gross | 5.6% | |||||
|
Soleno Therapeutics, Inc.
13G/A
SLNO · 834203309
|
6.4% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 6.4% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 6.4% | |||||
| Phillip Gross | 6.4% | |||||
|
Shattuck Labs, Inc.
13G/A
STTK · 82024L103
|
9.8% |
2/12/2025
Event 12/31/2024
|
||||
| Adage Capital Management, L.P. | 9.8% | |||||
| Adage Capital Partners GP, L.L.C. | 0% | |||||
| Robert Atchinson | 9.8% | |||||
| Phillip Gross | 9.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.